|Articles|February 1, 2003

Eye on Washington

With the election of Senator Bill Frist, MD (R-Tenn.), as leader of the Senate, physicians can expect health-related issues to receive intense and sympathetic attention in Congress.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

Safety, tolerability of tenapanor in pediatric IBS-C patients, with Thomas Wallach, MD

ByThomas Wallach, MD

November 7th 2025

Odevixibat demonstrates sustained pruritus and bile acid improvements in FIC1 deficiency

ByJoshua Fitch, Senior Editor

November 7th 2025

Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C

ByJulie Khlevner, MD, AGAF

November 7th 2025

Linaclotide demonstrates positive long-term safety

ByJoshua Fitch, Senior Editor

November 6th 2025

Doxycycline for post-exposure prevention of Lyme disease in young children | Contemporary Pediatrics

Wesley Kufel, PharmD, discusses doxycycline for post-exposure prevention of Lyme disease in young children

ByWesley Kufel, PharmD, BCPS, BCIDP, FCCP, FIDSA

November 6th 2025

Latest CME

Video

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Jay B. Wish, MD

Multimedia

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Eye on Washington

Newsletter

Related Content

Safety, tolerability of tenapanor in pediatric IBS-C patients, with Thomas Wallach, MD

Odevixibat demonstrates sustained pruritus and bile acid improvements in FIC1 deficiency

Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C

Linaclotide demonstrates positive long-term safety

Wesley Kufel, PharmD, discusses doxycycline for post-exposure prevention of Lyme disease in young children

Latest CME

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

Safety, tolerability of tenapanor in pediatric IBS-C patients, with Thomas Wallach, MD

Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C

Odevixibat demonstrates sustained pruritus and bile acid improvements in FIC1 deficiency